Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003
Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076.
2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8)
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 2014; 311:507-520.
2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Mancia G, Fagard R, Narkiewicz K, Redon J, Zancketti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009)
Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
ACCOMPLISH trial investigators
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial
Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29:1649-1659.
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study
ORIENT study investigators
Imai E, Chan JC, Ito S, Kobayashi F, Haneda M, Makino H, ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54:2978-2986.
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
ROADMAP trial investigators
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: The OMEGA study
OMEGA study group
Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Shirayama M, Hiramatsu K, Kobayashi F, OMEGA Study Group. Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study. Hypertens Res 2012; 35:1136-1144.
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients
Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716-723.
COLM study investigators, Rationale, study design and implementation of the COLM study: The Combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients
Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, et al., COLM Study Investigators. Rationale, study design and implementation of the COLM study: the Combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32:163-167.
The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)
Japanese Society of Hypertension
Japanese Society of Hypertension. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29:S1-S105.
Current usage of diuretics among hypertensive patients in Japan: The Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) Study
J-home study group
Murai K, Obara T, Ohkubo T, Metoki H, Oikawa T, Inoue R, et al., J-Home Study Group. Current usage of diuretics among hypertensive patients in Japan: the Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 2006; 29:857-863.
Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
ASCOT Investigators
Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
Blood Pressure Lowering Treatment Trialists' CollaborationTurnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951-958.
Blood Pressure Lowering Treatment Trialists' CollaborationTurnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008; 336:1121-1123.
Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:42-50.